{"id":"NCT01424813","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma","officialTitle":"A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2013-10","completion":"2013-11","firstPosted":"2011-08-29","resultsPosted":"2015-05-20","lastUpdate":"2015-06-26"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Placebo MDPI","otherNames":["Placebo Spiromax®"]},{"type":"DRUG","name":"Albuterol MDPI","otherNames":["ProAir® RespiClick, Albuterol Spiromax®"]}],"arms":[{"label":"Placebo MDPI","type":"PLACEBO_COMPARATOR"},{"label":"Albuterol MDPI","type":"EXPERIMENTAL"}],"summary":"The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax® or placebo.","primaryOutcome":{"measure":"Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period","timeFrame":"Day 1, Day 8 and Day 85","effectByArm":[{"arm":"Placebo MDPI","deltaMin":0.28,"sd":0.091},{"arm":"Albuterol MDPI","deltaMin":1.11,"sd":0.092}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":9},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["26369589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Upper respiratory tract infection","Headache"]}}